增持计划基本情况：江苏亚虹医药科技股份有限公司（ 以下简称（ 公司"） 于 2024 年 2 月 5 日披露了《江苏亚虹医药科技股份有限公司关于公司 控股股东、实际控制人、董事长兼总经理及部分董事、高级管理人员增 持公司股份计划的公告》 公告编号：2024-009），公司控股股东、实 际控制人、董事长兼总经理 PAN KE 先生，董事、董事会秘书兼财务负 责人杨明远先生 以下合称 增持主体"）计划自 2024 年 2 月 5 日起 6 个月内，通过上海证券交易所系统允许的方式 包括但不限于竞价交 易和大宗交易等）增持公司股份，合计增持金额不低于人民币 400 万元 且不超过人民币 800 万元。 增持计划实施进展情况：2024 年 2 月 5 日至 2024 年 4 月 19 日期间， 增持主体通过上海证券交易所以集中竞价交易方式累计增持公司股份 656,729 股，占公司总股本的 0.1152%，增持金额合计人民币 390.45 万 元（ 不含印花税、交易佣金等交易费用）。截至目前，增持主体已达到 并超过本次增持计划拟增持金额区间下限的 50%，本次增持股份计划尚 未实施完毕，增持主体将继续实施本次增持计划 ...

江苏亚虹医药科技股份有限公司 募集资金存放与使用情况 专项报告的鉴证报告 二〇二三年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行登录 关于江苏亚虹医药科技股份有限公司 2023年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2024]第ZA11212号 江苏亚虹医药科技股份有限公司全体股东: 我们接受委托,对后附的江苏亚虹医药科技股份有限公司(以下 简称"亚虹医药"或"公司")2023年度募集资金存放与使用情况专 项报告(以下简称"募集资金专项报告")执行了合理保证的鉴证业 务。 一、董事会的责任 亚虹医药董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》(证监会公告〔2022〕15号)、《上海证券交易所 科创板上市公司自律监管指引第1号 -- 规范运作》以及《上海证券 交易所上市公司自律监管指南第1号 -- 公告格式(2023年12月第二 次修订)》的相关规定编制募集资金专项报告。这种责任包括设计、 执行和维护与募集资金专项报告编制相关的内部控制,确 ...

江苏亚虹医药科技股份有限公司 信息披露管理制度 第一章 总则 前款"重大信息"，包括但不限于： 1 第一条 为确保江苏亚虹医药科技股份有限公司（以下简称"公司"）信息 披露的及时、准确、充分、完整，保护投资者合法权益，根据《中 华人民共和国公司法》《上市公司信息披露管理办法》《上海证券交 易所科创板股票上市规则》（以下简称"《上市规则》"）等法律、法 规、规范性文件及《江苏亚虹医药科技股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，结合公司的实际情况，特制 定本制度。 第二条 本制度所称信息披露，是当发生或即将发生可能对公司股票及其 衍生品的交易价格产生较大影响或者对投资决策有较大影响的信 息以及证券监管部门要求或公司主动披露的信息（以下简称"重 大信息"）时，根据法律、法规、规范性文件的规定及时将相关信 息的公告文稿和相关备查文件报送上海证券交易所登记，并在符 合中国证券监督管理委员会（以下简称"中国证监会"）规定条件 的媒体，以规定的方式向社会公众公布应披露的信息。信息披露文 件的形式主要包括：招股说明书、募集说明书、上市公告书、定期 报告和临时报告等。 （一） 与公司业绩、利润等事项有关的信 ...

一、独立董事的基本情况 （一）独立董事人员情况 公司第一届董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数三分 之一以上，符合相关法律法规及公司制度的规定。 公司于 2023 年 12 月 28 日完成换届选举工作，选举本人为公司第二届董事 会独立董事。第二届董事会由 9 名董事组成，其中独立董事 3 名，占董事会人数 三分之一以上，符合相关法律法规及公司制度的规定。 （二）个人工作履历、专业背景以及兼职情况 王文宁女士，1968 年出生，中国国籍，无境外永久居留权。王文宁女士于复 旦大学获得学士学位和博士学位。1996 年至今，于复旦大学化学系历任讲师、副 教授、教授及副系主任；2023 年 12 月至今，任公司独立董事。 （三）独立董事任职董事会专门委员会的情况 江苏亚虹医药科技股份有限公司 2023 年度独立董事述职报告 本人作为江苏亚虹医药科技股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《江苏亚虹医药科技股 份有限公司章程》（以下简称"《公司章程》"）、《上市公司独立董事管理办法》的 有关规定，本着对公司及全体股东负责的态度，以关注 ...

Stock Incentive Plan - The company implemented a restricted stock incentive plan in 2022, granting a total of 9,790,800 shares, accounting for 1.72% of the total shares, to 151 employees, representing 38.32% of the total workforce[4] - In 2023, the company granted an additional 1,925,000 restricted shares to 18 employees at a price of 6.79 RMB per share, with 4.22 million shares remaining unallocated and automatically expired[5][8] - The total share-based payment expense recognized in the reporting period for the 2022 restricted stock incentive plan was 16,400,970.53 RMB[9] - Key executives and core technical personnel, including the Chairman and CEO, were granted restricted shares, with the Chairman receiving 1.3 million shares and other executives receiving between 22,500 to 130,000 shares each[12] Financial Performance - Revenue for 2023 reached 13,753,343.12 yuan, a significant increase compared to 2022's 26,095.32 yuan[18] - Net profit attributable to shareholders in 2023 was -400,434,603.65 yuan, a decrease from -246,549,785.26 yuan in 2022[18] - Operating cash flow for 2023 was -398,186,688.82 yuan, down from -241,960,907.88 yuan in 2022[18] - Total assets at the end of 2023 were 2,632,270,467.20 yuan, a decrease of 8.41% compared to 2022[18] - Basic earnings per share for 2023 were -0.70 yuan, compared to -0.43 yuan in 2022[19] - Weighted average return on equity for 2023 was -15.52%, down from -8.52% in 2022[19] - Revenue in Q4 2023 was 10,757,271.87 yuan, the highest among all quarters[23] - Net profit attributable to shareholders in Q4 2023 was -132,390,991.55 yuan, the lowest among all quarters[23] - Government subsidies in 2023 amounted to 6,953,033.26 yuan, an increase from 5,929,193.05 yuan in 2022[24] - Non-recurring gains and losses in 2023 totaled 31,788,811.50 yuan, a decrease from 63,493,965.12 yuan in 2022[27] Asset and Investment Changes - The company's trading financial assets decreased by 1,108,968,660.80 RMB, from 1,703,276,190.24 RMB to 594,307,529.44 RMB, impacting the current profit by 23,932,781.55 RMB[31] - The company's other current assets increased by 14,544,364.54 RMB, impacting the current profit by 1,459,111.24 RMB[31] - The company's other equity instrument investments increased by 805,424.10 RMB, from 15,336,049.20 RMB to 16,141,473.30 RMB[31] Product Development and Clinical Trials - The company has 2 marketed products and 13 products in clinical and preclinical development, including 6 in clinical development, with APL-1702 and APL-1202 being global first-in-class drugs[38] - The company's APL-1202, in combination with tislelizumab, showed a significant increase in histological response rate in a Phase II clinical trial for muscle-invasive bladder cancer[35] - The company is preparing to submit an NDA for APL-1702 to the NMPA and is discussing a Phase III clinical trial plan with the FDA for the US market[35] - APL-1202 combined with chemotherapy for recurrent NMIBC did not meet the primary endpoint in the ACCRUE study, leading to the termination of further development in this indication[75] - In the ASCERTAIN study, APL-1202 monotherapy showed similar non-recurrence rates compared to chemotherapy in untreated intermediate-risk NMIBC patients, with 8 out of 21 patients completing over 1 year of treatment[78] - APL-1202 combined with Tislelizumab in the ANTICIPATE study showed a pCR rate of 39% vs 21% for Tislelizumab alone, with promising efficacy signals in MIBC patients[79] - The ANTICIPATE study is expected to release top-line Phase II data in Q3 2024, with plans to prioritize clinical development in China for advanced bladder cancer[80] - APL-1501, a second-generation product of APL-1202, is undergoing Phase I trials in Australia, aiming to improve efficacy and reduce side effects with better pharmacokinetic properties[83] - The company plans to initiate clinical studies in the US for APL-1501 combined with immune checkpoint inhibitors for BCG-unresponsive NMIBC patients, with discussions with FDA planned for 2024[83] - APL-1202 combined with immune checkpoint inhibitors is expected to improve the efficacy of advanced bladder cancer patients, with a current single-agent ORR of only around 25%[84] - APL-1706, a diagnostic imaging agent for bladder cancer, has been approved in over 30 countries and completed Phase III clinical trials in China, showing a 43.3% additional detection rate of bladder cancer lesions compared to standard white light cystoscopy[85] - APL-1706's Phase III clinical trial demonstrated an additional detection rate of ≥1 CIS lesion in 9.6% of subjects, with real-world studies showing a 7.1% additional detection rate[85] - APL-1706's New Drug Application (NDA) was accepted by the National Medical Products Administration in November 2023, with expected approval by June 2025[88] - APL-1702 showed a significant improvement in response rate by 89.4% compared to placebo (41.1% vs. 21.7%, p = 0.0001) in its Phase III clinical trial[90] - APL-1702 demonstrated a 41.4% improvement in HPV clearance rate in the mITT population (28.0% vs. 19.8%) and a 103.9% improvement for high-risk HPV16 and/or HPV18 (31.4% vs. 15.4%)[90] - APL-1702's Phase III clinical trial results were selected for oral presentations at the 2024 EUROGIN and SGO conferences[91] - APL-1702 Phase III clinical trial enrolled 402 patients from multiple countries including China, Germany, and the Netherlands[120] - The trial evaluates the efficacy and safety of APL-1702 for HSIL, with primary endpoint being response rate at 6 months post-treatment[120] - Response rate and HPV16+/HPV18+ clearance rate were compared between APL-1702 and placebo groups[121] - APL-1702 is expected to redefine the treatment goals for cervical precancerous lesions, shifting focus from one-time surgical outcomes to long-term disease management, aiming to balance treatment risks and benefits while avoiding or delaying invasive surgeries[123] - The company plans to submit a pre-submission communication to the European Medicines Agency (EMA) for APL-1702 in Q3 2024 and aims to discuss registration clinical trial designs with the US FDA for the North American market in 2024[123] - APL-1401, a novel oral drug for ulcerative colitis (UC), is undergoing Ib phase clinical trials in 12 centers across China and the US, with completion expected in 2025[124] - APL-2301, a novel antibacterial drug for Acinetobacter baumannii infections, has been approved for Phase I clinical trials in Australia, focusing on safety, tolerability, and pharmacokinetics[128] - The company is developing APL-2302, a USP1 inhibitor, which has shown strong tumor-killing effects in preclinical studies and is planned for clinical trial applications in 2024[129][130][131] - APLD-2304, a portable blue-light bladder soft scope, is being developed to improve specificity and reduce false positives in bladder cancer diagnosis, with ongoing exploration of overseas commercialization opportunities[132][135] - AT-014, a high-selective growth factor receptor inhibitor, is being optimized using AI technology for treating bladder cancer and other advanced solid tumors[136] - AT-017, an epigenetic-related small molecule oral drug, is being developed for urogenital system tumors, with ongoing lead compound optimization using TAIDD platform[137] - AT-018 is a self-developed small molecule oral drug targeting cell cycle-related pathways, specifically for treating female-related cancers such as breast cancer, ovarian cancer, and endometrial cancer. The company utilizes the TAIDD platform for multi-conformation simulation and AI for compound optimization[138] - AT-020 is a next-generation ADC drug targeting new tumor antigens, with potential to address unmet clinical needs in bladder and breast cancers. Existing ADC drugs like Enfortumab Vedotin show an ORR of 50%-60% in advanced urothelial cancer, indicating significant room for improvement[139] - AT-021 is an ADC drug aimed at enhancing anti-tumor immunity by combining self-developed immune-boosting small molecules with targeted antibodies. It aims to improve efficacy and reduce side effects of current immunotherapies like CTLA-4 and PD-1 antibodies[140] - APL-1702, a photodynamic medical device combination product, is being developed for cervical high-grade squamous intraepithelial lesions, with plans to submit a Phase III clinical trial application to the FDA[146] - APL-1202, targeting MetAP2, is in development for untreated intermediate-risk NMIBC and as a neoadjuvant therapy for MIBC in combination with tislelizumab[146] - APL-1501, a second-generation APL-1202, is being developed for urological tumors, with clinical trials planned in Australia[146] - AT-014 and AT-020 are in development for urological tumors and various solid tumors, respectively, leveraging the TAIDD and ADC platforms[146] - APL-2302, targeting USP1, is being developed for ovarian and breast cancers, with global rights[146] Commercialization and Market Access - The company's oncology division has rapidly built a nearly 200-person commercialization team, aiming for over 100 million RMB in sales and internal break-even in 2024[39] - The company's HCCM platform has over 8,000 users, with more than 85% of registered doctors being from relevant fields, and nearly 1,500 interactions in the breast cancer field[40] - The company achieved sales of 9.2892 million yuan for its oncology products, including Dypate and Ouyoubi, by the end of the reporting period[63] - The company's oncology products, Dypate and Ouyoubi, achieved coverage in 80% of target cities by Q4 2023 and 100% by Q1 2024[68] - Dypate achieved sales in over 70% of target key hospitals within six months of launch, while Ouyoubi connected with major customers and benefited over 1,000 patients within three months of launch[68] - The company's market access team achieved 90% provincial bidding and dual-channel access for its oncology products[68] - The company established a Women's Health Division in early 2024 to focus on the commercialization of APL-1702 and expand its gynecological product pipeline[72] - The company is actively promoting the overseas development and collaboration opportunities for APL-1202/APL-1501 and exploring commercialization opportunities for a disposable blue-light cystoscope in the US clinic market[66] - The company is focusing on localizing production of imported drugs and devices to establish a reliable and agile supply chain while reducing costs[93] - The company is committed to providing optimal diagnostic and therapeutic solutions for bladder cancer, with a product portfolio covering NMIBC diagnosis, surgery, treatment, and follow-up[96] Environmental and Social Responsibility - The company invested 692,300 yuan in environmental protection during the reporting period[49] - The company consumed 1,921.52 tons of water and 908,100 kWh of electricity during the reporting period[51] - The company has implemented strict environmental management systems, including waste classification and hazardous waste disposal through qualified third-party companies[55][56] - The company released its first ESG report in 2023, integrating environmental, social, and governance factors into its strategic development to provide more decision-making information for investors[142] Shareholder and Employee Commitments - Employee stock ownership accounts for 4.28% of the total share capital[102] - Number of employees holding shares is 43, representing 10.91% of the total workforce[103] - Total employee shareholding is 2,437,600 shares[103] - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of listing, and will not propose the company to repurchase these shares[155] - If the company's stock price remains below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for pre-listing shares will be automatically extended by 6 months[155] - In the event of major illegal activities leading to delisting, shareholders commit not to sell their shares from the date of the administrative penalty or judicial decision until the stock is delisted[155] - Shareholders who violate the share lock-up commitments must publicly explain the reasons and apologize to shareholders and the public, with any illegal gains from share sales to be returned to the company[155] - Certain shareholders, including Pan-Scientific, have committed to a 36-month lock-up period from the listing date, with similar penalties for violations[155] - Other shareholders, such as Taizhou Donghong and Taizhou Yahong, also have a 36-month lock-up period from the listing date, with additional commitments in case of delisting due to illegal activities[157] - Some shareholders, including Nanjing Ruike and QM139, have a lock-up period of 12 months from the listing date or 36 months from the completion of the industrial and commercial registration changes, whichever is longer[157] - Directors and senior management have a 12-month lock-up period from the listing date, with additional restrictions if the company is not profitable at the time of listing[160] - If the company is not profitable at the time of listing, directors and senior management cannot sell their pre-listing shares for 3 full fiscal years, and must comply with relevant regulations even after leaving the company[160] - In case of stock price falling below the issue price for 20 consecutive trading days within 6 months of listing, the lock-up period for directors and senior management will be automatically extended by 6 months[160] - The company's core technical personnel are subject to a 12-month lock-up period from the date of listing, and a 6-month lock-up period after resignation, during which they cannot transfer or entrust others to manage their shares[166] - Core technical personnel can only transfer up to 25% of their pre-IPO shares annually for 4 years after the lock-up period expires[166] - The company's directors, supervisors, and senior management are restricted from transferring more than 25% of their total shares annually after the lock-up period[163] - If the company is not profitable at the time of listing, core technical personnel cannot reduce their pre-IPO shares for 3 full fiscal years[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is not profitable at the time of listing for 3 full fiscal years[163] - The company's directors, supervisors, and senior management cannot reduce their shares within 6 months after resignation[163] - The company's core technical personnel cannot reduce their shares within 6 months after resignation[166] - The company's directors, supervisors, and senior management cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[163] - The company's core technical personnel cannot reduce their shares if the company is involved in major illegal activities that trigger delisting[166] - The company's directors, supervisors, and senior management must publicly explain and apologize if they violate the share reduction commitments[163] - The company plans to reduce its shareholding by no more than 100% of its total shares within two years after the lock-up period expires, with the selling price not lower than the audited net asset value per share at the end of the previous fiscal year[173] - The company will initiate stock price stabilization measures if the stock price remains below the audited net asset value per share for 20 consecutive trading days within three years of listing[172] - The company will hold a board meeting within 10 days to pass a resolution on stock repurchase and submit it to the shareholders' meeting for approval if the stock price stabilization conditions are met[172] - The company will use its own funds for stock repurchase, with the repurchase price not exceeding the latest audited net asset value per share[172] - The company will repurchase shares through centralized bidding, tender offers, or other methods approved by securities regulators, with the annual repurchase amount not exceeding 50% of the net profit attributable to the parent company's shareholders in the most recent audited fiscal year[175] - If the company's stock price remains above the audited net asset value per share for three consecutive trading days, the repurchase plan will be terminated[175] - The controlling shareholder's share purchase plan will not exceed 20% of the after-tax cash dividends received from the company in the previous year, and the purchase price will not exceed the audited net asset value per share in the most recent fiscal year[175] - Directors and senior management will purchase shares within 90 days after the controlling shareholder's plan is completed, with the purchase amount not exceeding 20% of their after-tax compensation from the company in the previous year[178] - The company will cancel repurchased shares within 10 days after the completion or termination of the repurchase plan and proceed with the capital reduction process[175] - The company will extend the period for six months after expiration and return the after-tax cash dividends received from the company in the most recent fiscal year. If not returned on time, the company may deduct from future cash dividends until the cumulative deduction reaches the total after-tax cash dividends received in the most recent fiscal year[181] - If directors or senior management fail to fulfill their commitments to stabilize stock prices within three years of listing, they must publicly explain the reasons, apologize, and propose supplementary or alternative commitments. Additionally, 20% of their monthly after-tax salary will be deducted until the cumulative deduction reaches 20% of their after-tax salary from the most recent fiscal year[181] - In case of false statements or major omissions in the prospectus that significantly affect the company's compliance with legal issuance conditions, the company will repurchase all newly issued shares. The repurchase price will be determined according to regulatory documents and will not be lower than the market price at the time of repurchase[181] - If the company violates

1 术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；市场营销策划 （除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 二、修订《公司章程》的情况 证券代码：688176 证券简称：亚虹医药 公告编号：2024-028 江苏亚虹医药科技股份有限公司 关于增加经营范围、修订《公司章程》及部分内部 管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日 召开第二届董事会第五次会议，审议通过了《关于增加公司经营范围、修订<江 苏亚虹医药科技股份有限公司章程>及部分内部管理制度的议案》。现将有关事 项公告如下： 一、公司经营范围变更情况 根据公司经营发展需要和实际情况，结合公司战略发展规划，拟增加公司经 营范围。 变更前的经营范围：医药产品的技术研发、咨询服务；自营和代理各类商品 及技术的进出口业务（国家限定公司经营或禁止进出口的商品和技术除外）。（依 法须经批准的项目，经相关部门批准后方可开展经营活动）许可项目：药品生产； ...

江苏亚虹医药科技股份有限公司 第一章 总 则 第一条 为规范江苏亚虹医药科技股份有限公司（以下简称"公司"）与关 联方之间的关联交易，保证公司与关联方之间所发生的交易符合公 平、公开、公正的原则，维护公司与全体股东的合法权益，根据《中 华人民共和国公司法》《上海证券交易所科创板股票上市规则》等 相关法律、法规、规范性文件及《江苏亚虹医药科技股份有限公司 章程》（以下简称"《公司章程》"），并参照中国证券监督管理 委员会（以下简称"中国证监会"）、证券交易所的相关规定，特制 定本制度。 第二章 关联交易和关联人的界定 1 第二条 关联交易是指公司或其合并报表范围内的子公司与公司关联人之 间发生的可能导致转移资源、劳务或义务的行为（不论是否收取价 款），主要包括： （一） 购买或者出售资产； （二） 对外投资（购买银行理财产品的除外）； （三） 转让或受让研发项目； （四） 签订许可使用协议； （五） 提供担保； （六） 租入或者租出资产； （七） 委托或者受托管理资产和业务； （八） 赠与或者受赠资产； （九） 债权、债务重组； （十） 提供财务资助； （十一） 放弃权利（含放弃优先购买权、优先认缴出资权利等） ...

股东大会议事规则 第一章 总 则 公司在上述期限内不能召开股东大会的，应当报告公司所在地中国 证券监督管理委员会（以下简称"中国证监会"）派出机构和上海证 券交易所，说明原因并公告。 1 第一条 为了规范江苏亚虹医药科技股份有限公司（以下简称"公司"）的 行为，保证公司股东大会依法行使职权，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）等相关法律、法规和其他规范性文件及《江苏亚虹 医药科技股份有限公司章程》（以下简称"《公司章程》"）的相关 规定，制定本议事规则。 第二条 公司应当严格按照法律、行政法规、《公司章程》及本议事规则的相 关规定召开股东大会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东大会。公司全体 董事应当勤勉尽责，确保股东大会正常召开和依法行使职权。 第三条 股东大会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东大会分为年度股东大会和临时股东大会。年度股东大会每年召 开一次，应当于上一会计年度结束后的 6 个月内举行。临时股东大 会不定期召开，出现《公司法》和《公司章程》规定的应当 ...

专项报告 2023 年度 您可使用手机"扫一扫"或进入"注册会计师行业结—唯一定的" al | P 关于江苏亚虹医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 立信会计师事务所关于江苏亚虹医药科技股份有限公司非经营性资金占用及其他关联 资金往来情况的专项报告 2、 关于江苏亚虹医药科技股份有限公司 2023 年度非经营性资金占用及其他关联资金往来 情况汇总表 委托单位：江苏亚虹医药科技股份有限公司 审计单位：立信会计师事务所（特殊普通合伙） 联系电话：021-23280000 江苏亚虹医药科技股份有限公司 关于江苏亚虹医药科技股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2024]第 ZA11211 号 江苏亚虹医药科技股份有限公司全体股东: 我们审计了江苏亚虹医药科技股份有限公司(以下简称"亚虹医 药")2023年度的财务报表,包括 2023年 12 月 31 日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注,并于 2024 年 4 月 1 ...

江苏亚虹医药科技股份有限公司 募集资金管理制度 第一章 总则 第二章 募集资金的存储 第五条 为方便募集资金的使用和对使用情况进行监督，公司实行募集资金专用 账户（下称"募集资金专户"）存储管理。设立募集资金专户事宜由公 司董事会批准。募集资金专户不得存放非募集资金或用作其它用途。 1 第一条 为规范江苏亚虹医药科技股份有限公司（以下简称"公司"）募集资金 的存储、使用与管理，提高募集资金的使用效率和效益，保障募集资金 的安全，维护投资者的合法权益，根据《中华人民共和国公司法》《中华 人民共和国证券法》（以下简称"《证券法》"）《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《监管规则适用指引 ——发行类第 7 号》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、 法规、规章、规范性文件以及《江苏亚虹医药科技股份有限公司章程》 （以下简称"《公司章程》"）的规定，结合公司的实际情况，制定本 制度。 第二条 本制度所称募集资金，是指公司通过向不特定对象公开发行证券（包括 首次公开发行股票、配股、增发、发行可转换公司债券、发 ...